# Comparison of the prevalence of sexual dysfunction in men diagnosed with schizophrenia taking clozapine or aripiprazole - URL: https://alisanburak.com/en/wcp-2026-posterler/ev1133 - Language: en - Last updated: not specified - Page title: Comparison of the prevalence of sexual dysfunction in men diagnosed with schizophrenia taking clozapine or aripiprazole | WCP 2026 Summary > Although sexual functioning is better in men taking aripiprazole than in those taking clozapine, antipsychotic type is no longer an independent predictor of se… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev1133) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV1133 E-PosterPsychopharmacologyCross-sectional study # Comparison of the prevalence of sexual dysfunction in men diagnosed with schizophrenia taking clozapine or aripiprazole COMPARISON OF THE PREVALENCE OF SEXUAL DYSFUNCTION IN MEN WITH SCHIZOPHRENIA TREATED WITH CLOZAPINE VERSUS ARIPIPRAZOLE Presenter: Razieh Salehian Country: Iran Although sexual functioning is better in men taking aripiprazole than in those taking clozapine, antipsychotic type is no longer an independent predictor of sexual functioning after adjustment for depression and psychosis severity. The aim was to compare the prevalence and severity of sexual dysfunction in men diagnosed with schizophrenia taking clozapine or aripiprazole and to examine the independent contributions of depressive and psychotic symptom severity to sexual dysfunction. In a cross-sectional study, 128 male patients who had been taking clozapine or aripiprazole for at least three months were assessed; sexual functioning was measured using the International Index of Erectile Function (IIEF), depressive symptoms using the PHQ-9, and psychotic symptom severity using the Brief Psychiatric Rating Scale (BPRS). Analyses included independent-samples t-tests, chi-square tests, ANOVA, Spearman correlations, and multivariable regression. The total IIEF score was 26.68 ± 17.81 in the aripiprazole group and 18.82 ± 14.93 in the clozapine group (p = 0.010). The aripiprazole group scored higher in the domains of erectile function (9.62 ± 8.49 versus 5.92 ± 7.06; p = 0.011), sexual desire (5.53 ± 1.49 versus 4.68 ± 2.01; p = 0.010), and intercourse satisfaction (3.65 ± 4.29 versus 1.92 ± 2.98; p = 0.011); differences in orgasmic function (p = 0.132) and overall satisfaction (p = 0.076) were not significant. Across the entire sample, the total BPRS score was 51.31 ± 14.76, and the mean depression severity score was 12.85 ± 5.51; correlations were rho = -0.553 between total IIEF and total PHQ scores, rho = -0.523 between total BPRS and total IIEF scores, and rho = 0.514 between total BPRS and total PHQ scores (all p < 0.001). In the multiple linear regression predicting total IIEF scores, depression (B = -1.198; p < 0.001) and psychosis (B = -0.373; p < 0.001) were significant predictors, whereas antipsychotic type was not (B = -0.419; p = 0.872). The authors noted that although aripiprazole initially appeared to have a more favorable sexual side-effect profile than clozapine, sexual dysfunction was more strongly associated with the severity of co-occurring depression and residual psychotic symptoms; clinicians should therefore actively screen for and treat underlying psychiatric symptoms. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1561) How to cite this study APA 7: Salehian, R., et al. (2026, September 23-26). Comparison of the prevalence of sexual dysfunction in men with schizophrenia treated with clozapine versus aripiprazole [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1561 Vancouver: Salehian R, et al. Comparison of the prevalence of sexual dysfunction in men with schizophrenia treated with clozapine versus aripiprazole [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1561 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev1133 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim